Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/06/2007US7291618 (3,3-Difluoropyrrolidin-1-yl)-((2S,4S)-4-(4-(pyrimidin-2-yl) piperazin-1-yl)pyrrolidin-2-yl)methanone, usedin treating diabetic complications including diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, and the like.
11/06/2007US7291617 Arylamidine derivative or salt thereof
11/06/2007US7291616 Such as 6(5-chloro-2-methoxyphenyl)-N-(4-chlorophenyl)-(1,3,5) triazine-2,4-diamine for inhibition of lysophosphatidic acid acyltransferase (LLPAAT-SS); antitumor agents
11/06/2007US7291615 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents
11/06/2007US7291614 Catalytic hydrogenation of R N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide to form the methylamine using a aromatic hydrocarbon or aromatic chlorohydrocarbon solvent; fewer by-products; may be acetylated to prepare linezolid without complicated purification steps
11/06/2007US7291613 Inhibitors of p38 kinase
11/06/2007US7291612 Immunomodulatory compounds
11/06/2007US7291611 Including indanones, indolinones and benzoxazolinones containing a piperidine ring, e.g., 1-[3-(4-(Hydroxymethyl)piperidin-1-yl)propyl]-1,3-dihydrobenzoimidazol-2-one; particularly for the M1 and/or M4 receptor subtypes; increase acetylcholine signaling or effect in the brain
11/06/2007US7291610 Estrogenic compounds as anti-mitotic agents
11/06/2007US7291609 Specific glucocorticosteroid compound having anti-inflammatory activity
11/06/2007US7291608 Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
11/06/2007US7291607 Administering to the animal an effective amount of one or more maltsoyl-isomaltooligosaccharides having a degree of polymerization less than or equal to 7, such that number of beneficial intestinal bacteria increase substantially or that the number of pathogenic bacteria decrease
11/06/2007US7291606 Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
11/06/2007US7291605 Methods of treating various cancers using melanoma differentiation associated protein-7
11/06/2007US7291604 Administering to tissue, such as blood vessel and active nucleic acids ; insertion of stents; cardiovascular disorders
11/06/2007US7291603 Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
11/06/2007US7291602 11,12-lactone bicyclolides
11/06/2007US7291599 Such as amistatin and leuhistin; for control of inflammation; topical creams, gels, ointments
11/06/2007US7291596 For activating the non-proteolytically activated thrombin receptor
11/06/2007US7291458 Leptin-mediated gene-induction
11/06/2007US7291454 Comprises antisense olignucleotides, ribozymes, DNA and guide sequences; animal models; genetic engineering; for use in drug screening
11/06/2007US7291352 Nut extract having different alkaloid profile; reduced level of carcinogens; supercritical CO2 extraction; maintaining nutraceutical effects; rapidly dissolving tablets
11/06/2007US7291350 Compositions for diabetes treatment and prophylaxis
11/06/2007US7291347 Solubility, permeability, and bioavailability; oral dosage
11/06/2007US7291332 Inflammatory mediator antagonists
11/06/2007US7291330 MD-1 inhibitors as immune suppressants
11/06/2007US7291324 Method of bowel cleansing
11/06/2007US7291179 Filler mixtures comprising calcium sulfate, plasticizers and demineralized matrices
11/06/2007US7291165 Medical device for delivering biologically active material
11/06/2007CA2451519C Tablet comprising cetirizine and pseudoephedrine
11/06/2007CA2427576C Benzodiazepine derivatives as gaba a receptor modulators
11/06/2007CA2388564C Caspase inhibitor
11/06/2007CA2353527C Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
11/06/2007CA2267322C Pde iv inhibiting 2-cyanoiminoimidazole derivatives
11/06/2007CA2266556C Nmda (n-methyl-d-aspartate) antagonists
11/06/2007CA2263927C Heterocyclic thioesters and ketones
11/06/2007CA2246346C Method and compounds for inhibition of ribonucleases
11/06/2007CA2241666C Tricyclic compounds, their production and use
11/06/2007CA2230649C Medicine for a disease caused by infection of helicobacter
11/06/2007CA2212129C A method of preparing mixed glucosamine salts
11/06/2007CA2202058C Cyclic hexapeptides having antibiotic activity
11/06/2007CA2193129C Transdermal drug delivery system
11/06/2007CA2079881C Nucleotidic sequences coding for variable regions of .beta. chains of human t lymphocite receptors, corresponding peptidic segments and diagnostic and therapeutic applications
11/06/2007CA2079879C Nucleotidic sequences coding for alpha chain variable regions in human lymphocite receptors and applications thereof
11/01/2007WO2007124498A2 Method for treating malignancies of hematopoietic lineage
11/01/2007WO2007124494A2 Enantioselectve reactions catalyzed by chiral triazolium salts
11/01/2007WO2007124489A2 Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
11/01/2007WO2007124476A2 Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
11/01/2007WO2007124435A2 Detection of histone deacetylase inhibition
11/01/2007WO2007124433A1 Hemostatic compositions and methods for controlling bleeding
11/01/2007WO2007124424A2 Il-8 receptor antagonists
11/01/2007WO2007124423A2 Il-8 receptor antagonists
11/01/2007WO2007124394A1 Substituted biphenyl carboxylic acids and derivatives thereof
11/01/2007WO2007124383A2 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members
11/01/2007WO2007124372A2 Pharmaceutical formulations for iontophoretic methotrexate delivery
11/01/2007WO2007124358A2 Pharmaceutical formulations for iontophoretic drug delivery
11/01/2007WO2007124355A2 Vascular endothelial receptor specific inhibitors
11/01/2007WO2007124353A2 Antispermatogenic, spermicidal and/or antifungal composition and methods of using the same
11/01/2007WO2007124351A1 Terphenyl derivatives for treatment of alzheimer' s disease
11/01/2007WO2007124348A2 Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression
11/01/2007WO2007124337A1 Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
11/01/2007WO2007124331A2 Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
11/01/2007WO2007124329A1 Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
11/01/2007WO2007124322A1 Inhibitors of c-fms kinase
11/01/2007WO2007124321A1 Inhibitors of c-fms kinase
11/01/2007WO2007124319A1 Inhibitors of c-fms kinase
11/01/2007WO2007124318A1 Inhibitors of c-fms kinase
11/01/2007WO2007124316A1 Heterocyclic compounds as inhibitors of c-fms kinase
11/01/2007WO2007124288A1 Indazole compounds and methods for inhibition of cdc7
11/01/2007WO2007124274A1 Treating neoplasms
11/01/2007WO2007124250A2 Methods of treating hot flashes with formulations for transdermal or transmucosal application
11/01/2007WO2007124221A1 Methods of treating cell proliferative disorders by using pyrimidinediamine compounds
11/01/2007WO2007124171A2 Compositions and methods for treating trinucleotide repeat disorders
11/01/2007WO2007124169A2 Compositions and methods for transient receptor potential vanilloid (trpv) channel mediated treatments
11/01/2007WO2007124136A1 Use of 4-amino-piperidines for treating sleep disorders
11/01/2007WO2007124132A2 Polymeric compositions and methods of making and using thereof
11/01/2007WO2007124123A2 Method of treating inflammation
11/01/2007WO2007124110A2 Vasodialating dressing for use with intravenous catheters
11/01/2007WO2007124086A1 Induction of weight loss and the selective inhibition of ptp1b
11/01/2007WO2007124045A2 Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
11/01/2007WO2007124005A2 Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors
11/01/2007WO2007123995A2 Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
11/01/2007WO2007123984A2 Pre-mixed, ready-to-use pharmaceutical compositions
11/01/2007WO2007123955A2 Stable hydroalcoholic oral spray formulations and methods
11/01/2007WO2007123953A2 Phosphodiesterase 4 inhibitors
11/01/2007WO2007123936A1 Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
11/01/2007WO2007123892A2 Raf inhibitors and their uses
11/01/2007WO2007123868A2 Organic thiophosphate antiretroviral agents
11/01/2007WO2007123867A2 Stable solutions of prostaglandin and uses of same
11/01/2007WO2007123865A2 Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
11/01/2007WO2007123818A2 Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use
11/01/2007WO2007123800A2 Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
11/01/2007WO2007123779A2 Improved dosing and scheduling of oligomers
11/01/2007WO2007123740A2 Pharmaceutical compositions for promoting wound healing
11/01/2007WO2007123732A2 Antifungal and antiparasitic indoloquinoline derivatives
11/01/2007WO2007123723A2 Diagnosis and treatment of alzheimer's disease
11/01/2007WO2007123718A1 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES
11/01/2007WO2007123672A2 Cytokine-expressing cancer immunotherapy combinations
11/01/2007WO2007123581A1 Glucagon receptor antagonists, preparation and therapeutic uses
11/01/2007WO2007123579A2 Translational dysfunction based therapeutics